EGFR L718Q has been reported as one of the rare resistance mechanisms to osimertinib therapy in an EGFR L858R/T790M-positive lung adenocarcinoma patient, which might be sensitive to afatinib (46, 47). Here, EGFR is linked to lung adenocarcinoma.